NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

AVII77: Allowing that the FDA insisted on crossover after progression in the DCVax-L trial is aknowledging that they accepted PFS as a primary endpoint, period. Either that, or they are crooks, and you can't start with that as a premise. Or perhaps that is your premise. My vague recollection from reading your posts in IV is that you are very familiar with the FDA. Perhaps you have some inside info here.

Are you saying that you think PFS will not be good enough for approval, even for the mesenchymal group, or are you saying that the FDA will not ultimately accept PFS as the primary endpoint?